Martin Shkreli, whom chances are you’ll know as "Pharma Bro," launched a brand new firm final 12 months referred to as "Druglike, Inc." Now, the Federal Trade Commission (FTC) has requested a federal decide to carry him in contempt for failing to cooperate with the company in its investigation to find out whether or not launching the corporate violates his lifetime trade ban. US District Court Judge Denise Cote imposed a lifetime ban on Shkreli that prohibits him from taking part within the pharmaceutical trade early final 12 months. Cote dominated that the previous pharma exec orchestrated an unlawful anticompetitive scheme to achieve a monopoly over Daraprim, a life-saving anti-malarial and anti-parasitic drug.
After Shkreli's former firm, Turing Pharmaceuticals, obtained the manufacturing license for Daraprim, it raised the drug's costs from $17.50 to $750 per pill. Cote sided with the FTC within the antitrust lawsuit the company filed towards Shkreli in 2020 and ordered him to pay $64.6 million in damages, along with imposing…
2023-01-21 12:56:43
Original from www.engadget.com